MAY & BAKER NIGERIA PLC (MAYBAKER)
Nigerian Stock Exchange · Nigeria · prices in NGN · close of 21 Oct 2026
Key indicators
| Last close | NGN 39.75 |
|---|---|
| 52-week range | 15.70 – 52.50 |
| Return, 1 month / 3 months | +1.9% / −0.5% |
| Return, 1 year / 3 years | +123.9% / +717.9% |
| Trend | Uptrend |
| RSI (14) | 57 |
| Volatility (1 year) | 61.1% |
| Worst drawdown (1 year) | -30.8% |
| Average daily value traded | 20.91M NGN |
| Dividend yield | 1.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
May & Baker Nigeria is a pharmaceutical company based in Nigeria that makes and markets medicines and healthcare products. Its range includes pain relief and cold remedies, prescription medicines and other consumer health items sold through pharmacies, hospitals and distributors across the country. The company also provides contract manufacturing and related services from its production facilities, serving healthcare providers and households in the Nigerian market.
On this site MAY & BAKER NIGERIA PLC appears as a stock on the Nigerian Stock Exchange (Nigeria), code MAYBAKER, with prices in Nigerian naira (NGN). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
MAY & BAKER NIGERIA PLC (MAYBAKER) trades on the Nigerian Stock Exchange in Nigeria. It last closed at NGN 39.75 on 21 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 58 of 157 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 123.9% and over the last three months it fell 0.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nigerian Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.7% | ||
| From 52-week high | -23.6% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -0.5% | ||
| 6-month return | 4.6% | ||
| 12-month return, skipping the last month | 119.7% | ||
| Stability (higher is calmer) | 51 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 61.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.8% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 20.91M NGN | ||
| Zero-volume days | 0.0% | ||
| Income | 44 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.3% | ||
| Years with dividends | 5 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +1.9% |
| 3 months | −0.5% |
| 6 months | +4.6% |
| 1 year | +123.9% |
| 3 years | +717.9% |
| 5 years | +811.7% |
Signals
| 50-day / 200-day average | 38.57 / 39.10 |
|---|---|
| Golden / death cross (60 days) | Death, 6 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.38 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 May 2026 | NGN 0.5000 |
| 21 May 2025 | NGN 0.4000 |
| 22 May 2024 | NGN 0.3000 |
| 17 May 2023 | NGN 0.3000 |
| 18 May 2022 | NGN 0.3000 |
| 19 May 2021 | NGN 0.3000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nigerian Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.